MDL No. 3163

GLP-1 Vision Loss (NAION)

IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation

In the news

Announcement Illinois Lawyer Now (ISBA)IL

Ozempic and Vision Loss: What the FDA’s New NAION Warning Means in Illinois

On November 9, 2026, the FDA ordered every company that sells a GLP-1 drug to add a new warning to its label: a possible increased risk of NAION, a rare eye condition that can cause sudden and sometimes permanent vision loss. The order covers Ozempic, Wegovy, Mounjaro, Zepbound and every other GLP-1 on the market.... Continue Reading

Read at Illinois Lawyer Now (ISBA)

Announcement Illinois Lawyer Now (ISBA)IL

Illinois Medicaid Filled Nearly 1 Million Prescriptions for Leading GLP-1 Drugs Before the FDA’s Vision Loss Warning

Illinois Medicaid paid for 993,119 prescriptions for nine leading GLP-1 drugs between 2022 and 2025, at a gross cost of $1.1 billion. Every one was filled before November 9, 2026, when the FDA ordered manufacturers to add a warning about a rare form of permanent vision loss called NAION. Ankin Law analyzed four years of... Continue Reading

Read at Illinois Lawyer Now (ISBA)

Stories are matched on the docket number and on NAION, non-arteritic anterior ischemic optic neuropathy, with a litigation word in the same story for product names.

Docket facts

MDL number
3163
Docket type
Products Liability
Transferee court
Eastern District of Pennsylvania
Transferee judge
Karen S. Marston
Actions pending
247
Total actions to date
247

JPML pending-dockets report of October 1, 2026. Original report ↗

Also before Karen S. Marston